Login to Your Account



Ablynx, Eddingpharm Ink Chinese Pact on RANKL Inhibitor

By Cormac Sheridan
Staff Writer

Friday, October 18, 2013
europe_resized.jpg

Ablynx NV continues to crank out deals, its latest being a regional accord with Chinese specialty pharma firm Eddingpharm Co. Ltd. to develop and commercialize its anti-RANKL nanobody ALX-0141, for which it is receiving 2 million (US$2.7 million) up front, plus commercial milestones and tiered double-digit royalty payments.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription